{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:11Z","timestamp":1792839731789,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001610","name":"Falk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jhep.2021.01.032","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T10:58:17Z","timestamp":1612695497000},"page":"944-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":187,"title":["EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients"],"prefix":"10.1016","volume":"74","author":[{"given":"Markus","family":"Cornberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane S.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.01.032_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0002-9343(90)90423-B","article-title":"Response to hepatitis B vaccine in Alaska Natives with chronic alcoholism compared with non-alcoholic control subjects","volume":"88","author":"McMahon","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2021.01.032_bib3","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(03)00152-1","article-title":"Hepatitis B vaccines","volume":"39","author":"Shouval","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF01535747","article-title":"Hepatitis B vaccination - response of alcoholic with and without liver injury","volume":"33","author":"Mendenhall","year":"1988","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2021.01.032_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1572-0241.2007.01609.x","article-title":"Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases","volume":"103","author":"W\u00f6rns","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.032_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S Vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jhep.2021.01.032_bib7","doi-asserted-by":"crossref","first-page":"S579","DOI":"10.1016\/S0168-8278(20)31633-0","article-title":"Higher proportion of responders with hepatitis B antibody levels \u2265100 miu\/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)","volume":"73","author":"Vesikari","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-014-0375-9","article-title":"Old and new adjuvants for hepatitis B vaccines","volume":"204","author":"Leroux-Roels","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jhep.2021.01.032_bib9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib10","series-title":"COVID-19 vaccination in cancer patients: ESMO statements","year":"2020"},{"key":"10.1016\/j.jhep.2021.01.032_bib11","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2018","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2021.01.032_bib12","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"J\u00a0Immunother Canc"},{"key":"10.1016\/j.jhep.2021.01.032_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2021.01.032_bib14","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1200\/JOP.19.00495","article-title":"Safety of influenza vaccine in patients with cancer receiving pembrolizumab","volume":"16","author":"Failing","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jhep.2021.01.032_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.01.032_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A\u00a0phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.01.032_bib17","article-title":"Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update","volume":"8","author":"Bauman","year":"2020","journal-title":"J\u00a0Immunother Canc"},{"key":"10.1016\/j.jhep.2021.01.032_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(21)00008-X","article-title":"SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question","author":"Marjot","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S0264-410X(02)00510-8","article-title":"Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis","volume":"20","author":"Gaeta","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2021.01.032_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031070","article-title":"Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis","volume":"9","author":"H\u00e4rm\u00e4l\u00e4","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2021.01.032_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1086\/315245","article-title":"Pneumococcal vaccine response in cirrhosis and liver transplantation","volume":"181","author":"McCashland","year":"2000","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2021.01.032_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/jhep.2001.25883","article-title":"Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients","volume":"34","author":"Arguedas","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.032_bib23","article-title":"Two-dose hepatitis B vaccine (heplisav-B) results in better seroconversion than three-dose vaccine (engerix-B) in chronic liver disease","author":"Amjad","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2021.01.032_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/hepr.13008","article-title":"Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: a systematic review and meta-analysis","volume":"48","author":"Liu","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.01.032_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2000\/548206","article-title":"Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation","volume":"14","author":"Villeneuve","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.032_bib26","doi-asserted-by":"crossref","DOI":"10.1053\/jlts.2000.8313","article-title":"Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list","author":"Dom\u00ednguez","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2021.01.032_bib27","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1097\/TP.0000000000002012","article-title":"Vaccine recommendations for solid-organ transplant recipients and donors","volume":"102","author":"Stucchi","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2021.01.032_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13563","article-title":"Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Danziger-Isakov","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2021.01.032_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.12.021","article-title":"Management of infections pre- and post-liver transplantation: report of an AISF consensus\u00a0conference","author":"Fagiuoli","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib30","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","article-title":"Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation \u2013 a systematic review of randomized trials, observational studies and case re","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2021.01.032_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.healun.2018.03.001","article-title":"Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis","volume":"37","author":"Mulley","year":"2018","journal-title":"J\u00a0Hear Lung Transpl"},{"key":"10.1016\/j.jhep.2021.01.032_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056974","article-title":"Serologic vaccination response after solid organ transplantation: a systematic review","volume":"8","author":"Eckerle","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.01.032_bib33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4103\/1319-2442.164556","article-title":"Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis","volume":"26","author":"Karbasi-Afshar","year":"2015","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.jhep.2021.01.032_bib34","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/cid\/cix1081","article-title":"A\u00a0systematic review of safety and immunogenicity of influenza vaccination strategies in solid organ transplant recipients","volume":"66","author":"Chong","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2021.01.032_bib35","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1080\/21645515.2016.1201623","article-title":"Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: a systematic literature review and meta-analysis","volume":"12","author":"Liao","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jhep.2021.01.032_bib36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jis487","article-title":"Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology","volume":"206","author":"Beck","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2021.01.032_bib37","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","article-title":"A\u00a0systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349 year old patients","volume":"38","author":"\u00c9","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2021.01.032_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2019.101479","article-title":"Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: a systematic review and meta-analysis","volume":"32","author":"Garcia Garrido","year":"2019","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.jhep.2021.01.032_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/vaccines9010039","article-title":"A\u00a0COVID-19 vaccine: big strides come with big challenges","volume":"9","author":"Mellet","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.jhep.2021.01.032_bib40","first-page":"M21","article-title":"SARS-CoV-2 vaccines: much accomplished, much to learn","author":"Connors","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2021.01.032_bib41","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.01.032_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.01.032_bib43","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"Baden","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.01.032_bib44","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","author":"Voysey","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2021.01.032_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.01.005","article-title":"Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study","author":"L\u2019Huillier","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2021.01.032_bib46","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.032_bib47","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib48","article-title":"PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib49","doi-asserted-by":"crossref","first-page":"100169","DOI":"10.1016\/j.jhepr.2020.100169","article-title":"Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic","volume":"2","author":"Boettler","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.01.032_bib50","article-title":"Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study","author":"Marjot","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.032_bib51","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-012-0300-6","article-title":"Immunizations in chronic liver disease: what should be done and what is the evidence","volume":"15","author":"Leise","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhep.2021.01.032_bib52","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.autrev.2015.05.014","article-title":"On vaccine\u2019s adjuvants and autoimmunity: current evidence and future perspectives","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhep.2021.01.032_bib53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cvsm.2017.10.005","article-title":"Adverse reactions to vaccination: from anaphylaxis to autoimmunity","volume":"48","author":"Gershwin","year":"2018","journal-title":"Vet Clin North Am\u2013small Anim Pract"},{"key":"10.1016\/j.jhep.2021.01.032_bib54","first-page":"90","article-title":"Vaccines and autoimmune diseases of the adult","volume":"9","author":"Orbach","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.jhep.2021.01.032_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2021.01.032_bib56","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.07.074","article-title":"Autoimmune diseases after hepatitis B immunization in adults: literature review and meta-analysis, with reference to \u2018autoimmune\/autoinflammatory syndrome induced by adjuvants\u2019 (ASIA)","volume":"36","author":"Elwood","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2021.01.032_bib57","first-page":"E194","article-title":"HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature","volume":"59","author":"Genovese","year":"2018","journal-title":"J\u00a0Prev Med Hyg"},{"key":"10.1016\/j.jhep.2021.01.032_bib58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/art.30325","article-title":"Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study","volume":"63","author":"Gabay","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhep.2021.01.032_bib59","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3201\/eid2407.161783","article-title":"Registry cohort study to determine risk for multiple sclerosis after vaccination for pandemic influenza a(H1N1) with arepanrix, manitoba, Canada","volume":"24","author":"Mahmud","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhep.2021.01.032_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis","volume":"344","author":"Confavreux","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.01.032_bib61","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2021.01.032_bib62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(20)30125-4","article-title":"Determining risk factors for mortality in liver transplant patients with COVID-19","volume":"5","author":"Webb","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:17Z","timestamp":1759174877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0168827821000817"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.032","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}